AbstractMajor depressive disorder (MDD) is now an accepted disorder in children and adolescents; genetic studies and data that support a dysregulation of one or more neurotransmitter systems suggest that biological factors play an important role in MDD in children and adolescents.
Focused ultrasound for major depressive disorder Major depressive disorder (MDD) is the leading cause of disability worldwide, affecting 300 million people with a lifetime prevalence of 15%. Approximately one-third of all major depressive disorder patients fail to respond to currently established treatments based on medication and psychotherapy, thus falling into the category of Treatment-Resistant Depression (TRD) patients. In addition, 3 out of 4 patients in low and middle-income countries receive no treatment. Low-Intensity Focused Ultrasound (LIFU) is an emerging neuromodulation method for treating major depressive disorder which allows for non-invasive stimulation across the whole brain.
Major Depressive Disorder (MDD) has become a serious mental health problem with a lifetime prevalence of 15% to 20%. MDD is associated with significant morbidity, mortality, disability, and negative influence on patient's daily life This article is an overview of MDD, including its etiology, impacts, treatments, and recommendations for future perspective. The paper's results and discussion section will list the possible causes of MDD from biological, physiological, and social perspectives, such as physical active level and sleeping quality. Along with its impacts on individuals in social relationship, health and financial status. The article will also list several common treatment methods, for example, antidepressants, Electroconvulsive Therapy, and cognitive-behavioral therapy. Then provide some details regarding the perspective for the future. Overall, the readers could have a general overview to MDD. This paper is a review based on researches and studies collected using Google Scholar and PubMed Central in the field of MDD. Fundamental information about MDD is obtained from the Diagnostic and Statistical Manual of Mental Disorders: 5th edition. For the etiology section, the primary source is Dean's study, which provides comprehensive information about the etiology of MDD. The overview of treatment is based on Li's study , which provides a clinical guideline on MDD treatment process. The article will also reference several other academic sources such as Cui's study and Mullen's study in order to provides a comprehensive overview of MDD.
Of increasing importance in the civilian and military population is the recognition of major depressive disorder at its earliest stages and intervention before the onset of severe symptoms. Toward the goal of more effective monitoring of depression severity, we introduce vocal biomarkers that are derived automatically from phonologically-based measures of speech rate. To assess our measures, we use a 35-speaker free-response speech database of subjects treated for depression over a 6-week duration. We find that dissecting average measures of speech rate into phone-specific characteristics and, in particular, combined phone-duration measures uncovers stronger relationships between speech rate and depression severity than global measures previously reported for a speech-rate biomarker. Results of this study are supported by correlation of our measures with depression severity and classification of depression state with these vocal measures. Our approach provides a general framework for analyzing individual symptom categories through phonological units, and supports the premise that speaking rate can be an indicator of psychomotor retardation severity. ; United States. Dept. of Defense (Air Force Contract FA8721-05-C-0002)
Major depressive disorder: Brain signals as biomarkers for depression Tiago Costa from Delft University of Technology explores the potential of neuroimaging techniques, specifically non-invasive electroencephalography (EEG), in detecting biomarkers for depression. Major Depressive Disorder (MDD) is a prevalent and complex mental disorder posing significant challenges to both individuals and societies worldwide. An early and accurate diagnosis of depression is essential for effective treatment and management. In recent years, advancements in neuroimaging techniques have opened new avenues for identifying biomarkers that could aid in the diagnosis and understanding of depression. Among these techniques, non-invasive electroencephalography (EEG) has gained attention in the last decade for its potential to detect depression biomarkers. While there is significant heterogeneity in terms of methodologies, sample sizes, and research objectives, several consistent patterns and findings emerge.
Claudio Mencacci,1 Guido Di Sciascio,2 Pablo Katz,3 Claudio Ripellino31Ospedale Fatebenefratelli, Milan, Italy; 2Azienda Ospedaliera Universitaria Consorziale Policlinico di Bari, Bari, Italy; 3CSD Medical Research Srl, Milan, ItalyBackground: Depression has a lifetime prevalence of 10%–25% among women and 5%–12% among men. Selective serotonin reuptake inhibitors (SSRIs) are the most used and the most cost-effective treatment for long-term major depressive disorder. Since the introduction of generic SSRIs, the costs of branded drugs have been questioned. The objective of this study was to assess the cost-effectiveness (€ per quality-adjusted life year [QALY]) of escitalopram (which is still covered by a patent) compared with paroxetine, sertraline, and citalopram, the patents for which have expired.Methods: A decision analytic model was adapted from the Swedish Dental and Pharmaceutical Benefits agency model to reflect current clinical practice in the treatment of depression in Italy in collaboration with an expert panel of Italian psychiatrists and health economists. The population comprised patients with a first diagnosis of major depressive disorder and receiving for the first time one of the following SSRIs: escitalopram, sertraline, paroxetine, and citalopram. The time frame used was 12 months. Efficacy and utility data for the original model were validated by our expert panel. Local data were considered for resource utilization and for treatment costs based on the Lombardy region health service perspective. Several scenario simulations, one-way sensitivity analyses, and Monte Carlo simulations were performed to test the robustness of the model.Results: The base case scenario showed that escitalopram had an incremental cost-effectiveness ratio (ICER) of €4395 and €1080 per QALY compared with sertraline and paroxetine, respectively. Escitalopram was dominant over citalopram, which was confirmed by most one-way sensitivity analyses. The escitalopram strategy gained 0.011 QALYs more than citalopram, 0.008 more than paroxetine, and around 0.007 more than sertraline. Monte Carlo simulations indicated that ICER values for escitalopram were centered around €1100 and €4400 per QALY compared with paroxetine and sertraline, respectively. Although there is no official cost-effectiveness threshold in Italy, the value of €25,000 per QALY could be acceptable. All ICER values retrieved in all analyses were lower than this threshold.Conclusion: The findings from this cost-effectiveness analysis indicate that escitalopram could be accepted as a cost-effective strategy for the Lombardy region health service compared with the other SSRIs studied. The present assessment is based on ICER values resulting from this analysis, which are lower than the thresholds proposed by health care authorities in other European Union countries. These benefits are driven by the effectiveness of escitalopram, which result in an improved health-related quality of life, a higher probability of sustained remission, and better utilization of health care resources. The study results are robust and in line with other pharmacoeconomic analyses comparing escitalopram with other SSRIs.Keywords: CEA, depression, escitalopram, Lombardy, ICER, SSRI
BACKGROUND: Major depressive disorder (MDD) is a leading cause of disability worldwide. AIMS: To examine the: (a) 12-month prevalence of DSM-IV MDD; (b) proportion aware that they have a problem needing treatment and who want care; (c) proportion of the latter receiving treatment; and (d) proportion of such treatment meeting minimal standards. METHOD: Representative community household surveys from 21 countries as part of the World Health Organization World Mental Health Surveys. RESULTS: Of 51 547 respondents, 4.6% met 12-month criteria for DSM-IV MDD and of these 56.7% reported needing treatment. Among those who recognised their need for treatment, most (71.1%) made at least one visit to a service provider. Among those who received treatment, only 41.0% received treatment that met minimal standards. This resulted in only 16.5% of all individuals with 12-month MDD receiving minimally adequate treatment. CONCLUSIONS: Only a minority of participants with MDD received minimally adequate treatment: 1 in 5 people in high-income and 1 in 27 in low-/lower-middle-income countries. Scaling up care for MDD requires fundamental transformations in community education and outreach, supply of treatment and quality of services. ; The work contained in this paper is carried out in conjunction with the World Health Organization World Mental Health (WMH) Survey Initiative, which is supported by the National Institute of Mental Health (NIMH; R01 MH070884), the John D. and Catherine T. MacArthur Foundation, the Pfizer Foundation, the US Public Health Service (R13-MH066849, R01-MH069864, and R01 DA016558), the Fogarty International Center (FIRCA R03-TW006481), the Pan American Health Organization, Eli Lilly and Company, Ortho-McNeil Pharmaceutical, GlaxoSmithKline, Sanofi Aventis and Bristol-Myers Squibb. We thank the staff of the WMH Data Collection and Data Analysis Coordination Centres for assistance with instrumentation, fieldwork and consultation on data analysis. None of the funders had any role in the design, analysis, interpretation of results or preparation of this paper. A complete list of all within-country and cross-national WMH publications can be found at http://www.hcp.med.harvard.edu/wmh/. The Argentina survey – Estudio Argentino de Epidemiología en Salud Mental (EASM) – was supported by a grant from the Argentinian Ministry of Health (Ministerio de Salud de la Nación). The Bulgarian Epidemiological Study of common mental disorders EPIBUL is supported by the Ministry of Health and the National Center for Public Health Protection. The Chinese World Mental Health Survey Initiative is supported by the Pfizer Foundation. The Colombian National Study of Mental Health (NSMH) is supported by the Ministry of Social Protection. The Mental Health Study Medellín – Colombia was carried out and supported jointly by the Center for Excellence on Research in Mental Health (CES University) and the Secretary of Health of Medellín. The ESEMeD project is funded by the European Commission (Contracts QLG5-1999-01042; SANCO 2004123 and EAHC 20081308), (the Piedmont Region (Italy)), Fondo de Investigación Sanitaria, Instituto de Salud Carlos III, Spain (FIS 00/0028), Ministerio de Ciencia y Tecnología, Spain (SAF 2000-158-CE), Departament de Salut, Generalitat de Catalunya, Spain, Instituto de Salud Carlos III (CIBER CB06/02/0046, RETICS RD06/0011 REM-TAP), and other local agencies and by an unrestricted educational grant from GlaxoSmithKline. Implementation of the Iraq Mental Health Survey (IMHS) and data entry were carried out by the staff of the Iraqi MOH and MOP with direct support from the Iraqi IMHS team with funding from both the Japanese and European Funds through United Nations Development Group Iraq Trust Fund (UNDG ITF). The Israel National Health Survey is funded by the Ministry of Health with support from the Israel National Institute for Health Policy and Health Services Research and the National Insurance Institute of Israel. The World Mental Health Japan (WMHJ) Survey is supported by the Grant for Research on Psychiatric and Neurological Diseases and Mental Health (H13-SHOGAI-023, H14-TOKUBETSU-026, H16-KOKORO-013) from the Japan Ministry of Health, Labour and Welfare. The Lebanese National Mental Health Survey (LEBANON) is supported by the Lebanese Ministry of Public Health, the WHO (Lebanon), National Institute of Health/Fogarty International Center (R03 TW006481-01), Sheikh Hamdan Bin Rashid Al Maktoum Award for Medical Sciences, anonymous private donations to IDRAAC, Lebanon, and unrestricted grants from AstraZeneca, Eli Lilly, GlaxoSmithKline, Hikma Pharmaceuticals, Janssen Cilag, Lundbeck, Novartis and Servier. The Mexican National Comorbidity Survey (MNCS) is supported by The National Institute of Psychiatry Ramon de la Fuente (INPRFMDIES 4280) and by the National Council on Science and Technology (CONACyT-G30544-H), with supplemental support from the PanAmerican Health Organization (PAHO). The Psychiatric Enquiry to General Population in Southeast Spain – Murcia (PEGASUS-Murcia) Project has been financed by the Regional Health Authorities of Murcia (Servicio Murciano de Salud and Consejería de Sanidad y Política Social) and Fundación para la Formación e Investigación Sanitarias (FFIS) of Murcia. The Nigerian Survey of Mental Health and Wellbeing (NSMHW) is supported by the WHO (Geneva), the WHO (Nigeria), and the Federal Ministry of Health, Abuja, Nigeria. The Peruvian World Mental Health Study was funded by the National Institute of Health of the Ministry of Health of Peru. The Portuguese Mental Health Study was carried out by the Department of Mental Health, Faculty of Medical Sciences, NOVA University of Lisbon, with collaboration of the Portuguese Catholic University, and was funded by Champalimaud Foundation, Gulbenkian Foundation, Foundation for Science and Technology (FCT) and Ministry of Health. The Romania WMH study projects 'Policies in Mental Health Area' and 'National Study regarding Mental Health and Services Use' were carried out by National School of Public Health & Health Services Management (former National Institute for Research & Development in Health, present National School of Public Health Management & Professional Development, Bucharest), with technical support of Metro Media Transilvania, the National Institute of Statistics – National Centre for Training in Statistics, SC. Cheyenne Services SRL, Statistics Netherlands and were funded by Ministry of Public Health (former Ministry of Health) with supplemental support of Eli Lilly Romania SRL. The São Paulo Megacity Mental Health Survey is supported by the State of São Paulo Research Foundation (FAPESP) Thematic Project Grant03/00204-3. The Brazilian National Council for Scientific and Technological Development supports L.A. (CNPq Grant #307623/2013-0). The US National Comorbidity Survey Replication (NCS-R) is supported by the National Institute of Mental Health (NIMH; U01-MH60220) with supplemental support from the National Institute of Drug Abuse (NIDA), the Substance Abuse and Mental Health Services Administration (SAMHSA), the Robert Wood Johnson Foundation (RWJF; Grant 044708) and the John W. Alden Trust. G.T. is supported by the National Institute for Health Research (NIHR) Collaboration for Leadership in Applied Health Research and Care South London at King's College London Foundation Trust. G.T. is supported by the European Union Seventh Framework Programme (FP7/2007-2013) Emerald project. This paper is an output of the PRogramme for Improving Mental health carE (PRIME). The material has been funded by UK aid from the UK Government, however, the views expressed do not necessarily reflect the UK Government's official policies. The research supported by the National Institute for Health Research (NIHR) Collaboration for Leadership in Applied Health Research and Care South London at King's College London Foundation Trust. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health. The authors acknowledge financial support from the Department of Health via the National Institute for Health Research (NIHR) Biomedical Research Centre and Dementia Unit awarded to South London and Maudsley NHS Foundation Trust in partnership with King's College London and King's College Hospital NHS Foundation Trust. The views expressed in this paper are those of the authors and do not necessarily represent the views or policies of the World Health Organization
In light of Rational-Emotive Theory, this study was undertaken to determine the pattern of irrational beliefs underlying Major Depressive Disorder (MDD). A total of 126 subjects (50 males, 76 females) volunteered to participate. Patients clinically diagnosed with MDD (unipolar type) and a control group of non-depressed patients were solicited from the inpatient and outpatient facilities of several Ottawa and Montreal hospitals; the normal control group comprised students and civil servants. The subjects completed questionnaires to measure irrational belief endorsement (IBT, RBI) and symptom severity (STAI, BDI) and to verify the depression diganosis (IDD). Multivariate statistics were used to determine the pattern of beliefs which best discriminates between the MDD group, the psychiatric control group, and the normal controls. Discriminant analysis of the IBT revealed a pattern of four irrational beliefs generally known as demand for approval, frustration reactivity, anxious overconcern, and helplessness over past. The implications of such findings for RET theory are discussed.
LIFU for major depressive disorder - Targeting the neural networks of depression Tiago Costa, Assistant Professor at the Department of Microelectronics, Delft University of Technology, discusses opportunities surrounding low-intensity focused ultrasound in the treatment of major depressive disorder in a minimally invasive manner. Major depressive disorder (MDD) is a prevalent and debilitating mental health condition affecting millions worldwide. While various treatment options exist, including medication and psychotherapy, a significant proportion of individuals with MDD do not achieve full remission or experience adverse side effects from existing treatments. Consequently, there is a need for innovative and effective therapeutic approaches to address this complex disorder. One emerging and promising area of research is the use of low-intensity focused ultrasound (LIFU) to treat major depressive disorder. LIFU is a non-invasive technique that utilises ultrasound waves at lower intensities compared to high-intensity focused ultrasound (HIFU), which is used for the thermal ablation of tissue. By focusing these ultrasound waves on specific brain regions, LIFU has shown potential in modulating neural activity and potentially alleviating depressive symptoms.
Background: Experiences of discrimination have significant impact on the lives of people with mental illness. Aim: This study investigates the nature and severity of experienced and anticipated discrimination reported by persons with a depressive disorder in Serbia. Methods: Patients were recruited from two psychiatric day hospitals and a primary mental health service with a diagnosis of major depressive disorder. Interviews were conducted using a socio-demographic questionnaire and the Discrimination and Stigma Scale. Results: The respondents experienced discrimination mostly in the field of family relationships, making and keeping friends and keeping a job. In domains of making close personal relationships or applying for education, anticipated discrimination was higher than experienced. The need to conceal mental health problems was stronger than experiences of being avoided. The need to hide mental health problems was higher than the overall score for experienced discrimination. Participants who were hospitalized in some period of life reported higher experienced discrimination. Compared to younger participants, older participants experienced more negative as well as positive discrimination. Married participants experienced more negative discrimination than unmarried. Conclusion: It is important to design interventions to overcome discrimination toward persons with depression at all levels.
Major depressive disorder (MDD) is a devastating disease affecting over 300 million people worldwide, and costing an estimated 380 billion Euros in lost productivity and health care in the European Union alone. Although a wealth of research has been directed toward understanding and treating MDD, still no therapy has proved to be consistently and reliably effective in interrupting the symptoms of this disease. Recent clinical and preclinical studies, using genetic screening and transgenic rodents, respectively, suggest a major role of the CRF1 gene, and the central expression of CRF1 receptor protein in determining an individual's risk of developing MDD. This gene is widely expressed in brain tissue, and regulates an organism's immediate and long-term responses to social and environmental stressors, which are primary contributors to MDD. This review presents the current state of knowledge on CRF physiology, and how it may influence the occurrence of symptoms associated with MDD. Additionally, this review presents findings from multiple laboratories that were presented as part of a symposium on this topic at the annual 2014 meeting of the International Behavioral Neuroscience Society (IBNS). The ideas and data presented in this review demonstrate the great progress that has been made over the past few decades in our understanding of MDD, and provide a pathway forward toward developing novel treatments and detection methods for this disorder.